Englander Institute for Precision Medicine

Publications

Found 11 results
Author Title Type [ Year(Asc)]
Filters: Author is Necchi, Andrea  [Clear All Filters]
2023
Sternberg CN, Petrylak DP, Bellmunt J, Nishiyama H, Necchi A, Gurney H, Lee J-L, van der Heijden MS, Rosenbaum E, Penel N et al..  2023.  FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on / mRNA Expression.. J Clin Oncol. 41(3):629-639.
Necchi A, Faltas BM, Slovin SF, Meeks JJ, Pal SK, Schwartz LH, Huang RSP, Li R, Manley B, Chahoud J et al..  2023.  Immunotherapy in the Treatment of Localized Genitourinary Cancers.. JAMA Oncol. 9(10):1447-1454.
Lauritsen J, Sauvé N, Tryakin A, Jiang DMaria, Huddart R, Heng DYC, Terbuch A, Winquist E, Chovanec M, Hentrich M et al..  2023.  Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database.. Br J Cancer. 129(11):1759-1765.
2022
de Wit R, Powles T, Castellano D, Necchi A, Lee J-L, van der Heijden MS, Matsubara N, Bamias A, Fléchon A, Sternberg CN et al..  2022.  Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.. Br J Clin Pharmacol. 88(7):3182-3192.
van der Heijden MS, Powles T, Petrylak D, de Wit R, Necchi A, Sternberg CN, Matsubara N, Nishiyama H, Castellano D, Hussain SA et al..  2022.  Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.. Nat Commun. 13(1):1878.
Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee J-L, Fong L, Necchi A, Sternberg CN, O'Donnell PH et al..  2022.  Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.. Clin Cancer Res. 28(10):2050-2060.
2021
Wong RL, Ferris LA, Do OA, Holt SK, Ramos JD, Crabb SJ, Sternberg CN, Bellmunt J, Ladoire S, De Giorgi U et al..  2021.  Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.. Oncologist. 26(12):1026-1034.
Gillessen S, Sauvé N, Collette L, Daugaard G, de Wit R, Albany C, Tryakin A, Fizazi K, Stahl O, Gietema JA et al..  2021.  Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.. J Clin Oncol. 39(14):1563-1574.
Beyer J, Collette L, Sauvé N, Daugaard G, Feldman DR, Tandstad T, Tryakin A, Stahl O, Gonzalez-Billalabeitia E, De Giorgi U et al..  2021.  Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.. J Clin Oncol. 39(14):1553-1562.
2020
Grunewald CM, Henn A, Galsky MD, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AShivaram, Powles T et al..  2020.  Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival.. Urol Oncol. 38(12):934.e1-934.e9.
2019
Pederzoli F, Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN et al..  2019.  Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect.. Eur Urol. 76(4):425-429.